Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
14NOV

Astral raises £23m for cancer isotopes

2 min read
18:53UTC

Astral Systems, a Bristol deep-tech firm, raised £23m to make Actinium-225 and Lead-212, cancer-therapy isotopes now produced in only a handful of ageing reactors.

TechnologyDeveloping
Key takeaway

Astral's £23m round funds fusion-made cancer isotopes and shows how one large cheque can swing a UK region's total.

Astral Systems, a Bristol deep-tech firm, raised a £23m Series A to manufacture medical radioisotopes using its multi-state fusion reactors. The isotopes, Actinium-225 and Lead-212, are used in targeted cancer therapy, and the world produces them in a handful of ageing reactors. Mercia Ventures, a UK regional venture capital firm, led the round, with Tees River, Daphni, Blast Club, Speedinvest and Playfair Capital joining.

Astral runs several small fusion reactions at once rather than chasing grid power from one large tokamak, and it uses those reactions to breed isotopes that decay too fast to stockpile. That method attacks a supply bottleneck, because current output depends on a few reactors built decades ago, any one of which going offline can strand a therapy. Deep-tech investors, not energy utilities, backed the round, since the product on sale is a scarce medical input rather than electricity.

A lab-to-market round of this size lands rarely, and when it does it moves a region's annual figure on its own. This is part of the South West's outsized 2025 swing, the kind of single large cheque that lifts a regional share one year and vanishes the next. Unlike CuspAI's foreign-only cap table, this round kept a UK lead, and it lands in the same Bristol cluster where mycelium-materials firm Mykor raised £4m earlier in the cycle.

Deep Analysis

In plain English

Astral Systems is a Bristol company building reactors that make medical radioisotopes, rare radioactive materials used to treat cancer. Two of them, Actinium-225 and Lead-212, can be attached to drugs that hunt down tumour cells and destroy them from the inside. These isotopes are made in only a few old nuclear reactors around the world, and there is nowhere near enough to go round. Astral uses a fusion reaction to breed them instead. The company raised £23m to build its production line at a former power station site in Gloucestershire, with the first isotopes expected to reach patients around early 2027.

Deep Analysis
Root Causes

The scarcity of Actinium-225 and Lead-212 comes from their production route. Both are bred in nuclear reactions and decay within days, so they cannot be stockpiled and must be made close to where they are used. Global supply currently leans on a small number of ageing reactors and legacy material stocks, so any outage strands the cancer therapies and trials that depend on them.

Astral's modular multi-state design runs several smaller fusion reactions in parallel as a manufacturing method for these isotopes, not as a bid for grid power. That is why five funds with little prior fusion exposure, including European seed specialists Daphni and Speedinvest, were willing to write cheques into a Series A: the product on sale is a scarce medical input with an identified shortage, rather than speculative electricity a decade away.

First Reported In

Update #10 · AI takes record 44% as UK equity shrinks

UKTN· 4 Jul 2026
Read original →
Different Perspectives
Association of Investment Companies (Richard Stone)
Association of Investment Companies (Richard Stone)
The trust industry body criticised the Budget for leaving Venture Capital Trust relief at 20%. It had lobbied for the 30% rate to return.
Tax Justice UK
Tax Justice UK
The campaign group opposed the 10% founders' rate as a giveaway to a small group of wealthy owners. It said the BADR cut should have gone further, to abolition.
techUK
techUK
The trade body set the new relief against the BADR cut, which halves the most a seller can save to £30,000. It says the Budget takes back with BADR part of what it gives founders.
Startup Coalition
Startup Coalition
The founder lobby group welcomed the Budget package for startups. It treats the new relief as the strongest government support for founders in years.
HM Treasury
HM Treasury
The Treasury created a 10% founders' relief on up to £10m of lifetime gains and expects about 600 people a year to use it. It says the relief rewards founders behind the UK's fastest-growing companies.
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.